

Anders Snnerborg

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1882265/anders-sonnerborg-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

343
papers

12,006
citations

55
h-index

95
g-index

350
ext. papers

13,805
ext. citations

6.7
avg, IF

5.76
L-index

#	Paper	IF	Citations
343	Integrative proteo-transcriptomic and immunophenotyping signatures of HIV-1 elite control phenotype: A cross-talk between glycolysis and HIF signaling.. <i>iScience</i> , 2022 , 25, 103607	6.1	0
342	Novel Naturally Occurring Dipeptides and Single-Stranded Oligonucleotide Act as Entry Inhibitors and Exhibit a Strong Synergistic Anti-HIV-1 Profile.. <i>Infectious Diseases and Therapy</i> , 2022 , 1	6.2	0
341	Peripheral blood CD4CCR6 compartment differentiates HIV-1 infected or seropositive elite controllers from long-term successfully treated individuals.. <i>Communications Biology</i> , 2022 , 5, 357	6.7	
340	Characterization of the Upper Respiratory Bacterial Microbiome in Critically Ill COVID-19 Patients. <i>Biomedicines</i> , 2022 , 10, 982	4.8	0
339	Spectrum of Atazanavir-Selected Protease Inhibitor-Resistance Mutations. <i>Pathogens</i> , 2022 , 11, 546	4.5	0
338	Complex Mutation Pattern of Omicron BA.2: Evading Antibodies without Losing Receptor Interactions. <i>International Journal of Molecular Sciences</i> , 2022 , 23, 5534	6.3	0
337	Metabolic Perturbation Associated With COVID-19 Disease Severity and SARS-CoV-2 Replication. <i>Molecular and Cellular Proteomics</i> , 2021 , 20, 100159	7.6	16
336	Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatment-Experienced People Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2021 , 73, e2323-e2333	11.6	5
335	Cytotoxic Lymphocytes Target HIV-1 Gag Through Granzyme M-Mediated Cleavage. <i>Frontiers in Immunology</i> , 2021 , 12, 669347	8.4	0
334	Coronavirus helicases: attractive and unique targets of antiviral drug-development and therapeutic patents. <i>Expert Opinion on Therapeutic Patents</i> , 2021 , 31, 339-350	6.8	13
333	Pulmonary stromal expansion and intra-alveolar coagulation are primary causes of COVID-19 death. <i>Heliyon</i> , 2021 , 7, e07134	3.6	8
332	Whole-Genome Metagenomic Analysis of the Gut Microbiome in HIV-1-Infected Individuals on Antiretroviral Therapy. <i>Frontiers in Microbiology</i> , 2021 , 12, 667718	5.7	4
331	Contagiousness in treated HIV-1 infection. <i>Infectious Diseases</i> , 2021 , 53, 1-8	3.1	4
330	Altered Gut Microbiome under Antiretroviral Therapy: Impact of Efavirenz and Zidovudine. <i>ACS Infectious Diseases</i> , 2021 , 7, 1104-1115	5.5	3
329	Transmitted drug resistance to NRTIs and risk of virological failure in naïve patients treated with integrase inhibitors. <i>HIV Medicine</i> , 2021 , 22, 22-27	2.7	2
328	Evolution, correlation, structural impact and dynamics of emerging SARS-CoV-2 variants. <i>Computational and Structural Biotechnology Journal</i> , 2021 , 19, 3799-3809	6.8	12
327	HIV-1 CRF07_BC transmission dynamics in China: two decades of national molecular surveillance. <i>Emerging Microbes and Infections</i> , 2021 , 10, 1919-1930	18.9	4

326	High-throughput sequencing reveals a high prevalence of pretreatment HIV-1 drug resistance in Sweden. <i>Aids</i> , 2021 , 35, 227-234	3.5	0
325	Distinct lipid profile, low-level inflammation, and increased antioxidant defense signature in HIV-1 elite control status. <i>IScience</i> , 2021 , 24, 102111	6.1	6
324	Post-migration acquisition of HIV: Estimates from four European countries, 2007 to 2016. <i>Eurosurveillance</i> , 2021 , 26,	19.8	1
323	Delayed Treatment for People Living With HIV in China, 2004-2016: An Analysis of An Observational Cohort. <i>International Journal of Environmental Research and Public Health</i> , 2020 , 17,	4.6	3
322	Antiretroviral treatment for HIV infection: Swedish recommendations 2019. <i>Infectious Diseases</i> , 2020 , 52, 295-329	3.1	6
321	Chromatin maturation of the HIV-1 provirus in primary resting CD4+T cells. <i>PLoS Pathogens</i> , 2020 , 16, e1008264	7.6	9
320	HIV-1 Sub-Subtype A6: Settings for Normalised Identification and Molecular Epidemiology in the Southern Federal District, Russia. <i>Viruses</i> , 2020 , 12,	6.2	9
319	HPV Types in Cervical Precancer by HIV Status and Birth Region: A Population-Based Register Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020 , 29, 2662-2668	4	4
318	Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. <i>Cell</i> , 2020 , 183, 158-168.e14	56.2	955
317	Utility of Proteomics in Emerging and Re-Emerging Infectious Diseases Caused by RNA Viruses. <i>Journal of Proteome Research</i> , 2020 , 19, 4259-4274	5.6	14
316	Chromatin maturation of the HIV-1 provirus in primary resting CD4+ T cells 2020 , 16, e1008264		
315	Chromatin maturation of the HIV-1 provirus in primary resting CD4+ T cells 2020 , 16, e1008264		
314	Chromatin maturation of the HIV-1 provirus in primary resting CD4+ T cells 2020 , 16, e1008264		
313	Chromatin maturation of the HIV-1 provirus in primary resting CD4+ T cells 2020 , 16, e1008264		
312	Chromatin maturation of the HIV-1 provirus in primary resting CD4+ T cells 2020 , 16, e1008264		
311	MiDRM: A High-Throughput Multiplexed Amplicon Sequencing Workflow to Quantify HIV-1 Drug Resistance Mutations against Protease, Reverse Transcriptase, and Integrase Inhibitors. <i>Viruses</i> , 2019 , 11,	6.2	3
310	Earlier Initiation of Antiretroviral Treatment Coincides With an Initial Control of the HIV-1 Sub-Subtype F1 Outbreak Among Men-Having-Sex-With-Men in Flanders, Belgium. <i>Frontiers in Microbiology</i> , 2019 , 10, 613	5.7	8
309	Microfluidic centrifugation assisted precipitation based DNA quantification. <i>Lab on A Chip</i> , 2019 , 19, 1657-1664	5.1	7

308	Longer-term effectiveness of protease-inhibitor-based second line antiretroviral therapy in four large sub-Saharan African clinics. <i>Journal of Infection</i> , 2019 , 78, 402-408	18.9	1
307	Strain-specific effect on biphasic DNA binding by HIV-1 integrase. <i>Aids</i> , 2019 , 33, 588-592	3.5	6
306	GS-CA Compounds: First-In-Class HIV-1 Capsid Inhibitors Covering Multiple Grounds. <i>Frontiers in Microbiology</i> , 2019 , 10, 1227	5.7	27
305	A viral genome wide association study and genotypic resistance testing in patients failing first line antiretroviral therapy in the first large countrywide Ethiopian HIV cohort. <i>BMC Infectious Diseases</i> , 2019 , 19, 569	4	3
304	A5 Near full-length HIV-1 genome sequencing in newly diagnosed individuals in Sweden. <i>Virus Evolution</i> , 2019 , 5,	3.7	78
303	Challenges in modelling the proportion of undiagnosed HIV infections in Sweden. <i>Eurosurveillance</i> , 2019 , 24,	19.8	3
302	HIV-1 Subtype C with PYxE Insertion Has Enhanced Binding of Gag-p6 to Host Cell Protein ALIX and Increased Replication Fitness. <i>Journal of Virology</i> , 2019 , 93,	6.6	7
301	The effect of primary drug resistance on CD4+ cell decline and the viral load set-point in HIV-positive individuals before the start of antiretroviral therapy. <i>Aids</i> , 2019 , 33, 315-326	3.5	2
300	HIV elite control is associated with reduced TRAILshort expression. <i>Aids</i> , 2019 , 33, 1757-1763	3.5	4
299	Optimal probability weights for estimating causal effects of time-varying treatments with marginal structural Cox models. <i>Statistics in Medicine</i> , 2019 , 38, 1891-1902	2.3	5
298	Effect of dolutegravir in combination with Nucleoside Reverse Transcriptase Inhibitors (NRTIs) on people living with HIV who have pre-existing NRTI mutations. <i>International Journal of Antimicrobial Agents</i> , 2018 , 51, 733-738	14.3	15
297	Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs. <i>Clinical Infectious Diseases</i> , 2018 , 66, 893-903	11.6	75
296	Increase in transmitted drug resistance in migrants from sub-Saharan Africa diagnosed with HIV-1 in Sweden. <i>Aids</i> , 2018 , 32, 877-884	3.5	6
295	Prophylaxis and treatment of HIV-1 infection in pregnancy - Swedish Recommendations 2017. <i>Infectious Diseases</i> , 2018 , 50, 495-506	3.1	9
294	Transcriptomics and Targeted Proteomics Analysis to Gain Insights Into the Immune-control Mechanisms of HIV-1 Infected Elite Controllers. <i>EBioMedicine</i> , 2018 , 27, 40-50	8.8	15
293	Ex-vivo antiretroviral potency of newer integrase strand transfer inhibitors cabotegravir and bictegravir in HIV type 1 non-B subtypes. <i>Aids</i> , 2018 , 32, 469-476	3.5	26
292	Antiretroviral potency of 4'-ethynyl-2'-fluoro-2'-deoxyadenosine, tenofovir alafenamide and second-generation NNRTIs across diverse HIV-1 subtypes. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 2721-2728	5.1	10
291	Human Immunodeficiency Virus Type-1 Elite Controllers Maintain Low Co-Expression of Inhibitory Receptors on CD4+ T Cells. <i>Frontiers in Immunology</i> , 2018 , 9, 19	8.4	11

290	Structural Implications of Genotypic Variations in HIV-1 Integrase From Diverse Subtypes. <i>Frontiers in Microbiology</i> , 2018 , 9, 1754	5.7	11
289	Pretreatment drug resistance in a large countrywide Ethiopian HIV-1C cohort: a comparison of Sanger and high-throughput sequencing. <i>Scientific Reports</i> , 2018 , 8, 7556	4.9	19
288	Coreceptor Tropism and Maraviroc Sensitivity of Clonally Derived Ethiopian HIV-1C Strains Using an in-house Phenotypic Assay and Commonly Used Genotypic Methods. <i>Current HIV Research</i> , 2018 , 16, 113-120	1.3	
287	Temporal trends of transmitted HIV drug resistance in a multinational seroconversion cohort. <i>Aids</i> , 2018 , 32, 161-169	3.5	14
286	Characterization of Inducible Transcription and Translation-Competent HIV-1 Using the RNAscope ISH Technology at a Single-Cell Resolution. <i>Frontiers in Microbiology</i> , 2018 , 9, 2358	5.7	13
285	Baseline predictors of antiretroviral treatment failure and lost to follow up in a multicenter countrywide HIV-1 cohort study in Ethiopia. <i>PLoS ONE</i> , 2018 , 13, e0200505	3.7	16
284	Suppressive antiretroviral therapy associates with effective treatment of high-grade cervical intraepithelial neoplasia. <i>Aids</i> , 2018 , 32, 1475-1484	3.5	7
283	Limited immune surveillance in lymphoid tissue by cytolytic CD4+ T cells during health and HIV disease. <i>PLoS Pathogens</i> , 2018 , 14, e1006973	7.6	23
282	Increased replication capacity following evolution of PYxE insertion in Gag-p6 is associated with enhanced virulence in HIV-1 subtype C from East Africa. <i>Journal of Medical Virology</i> , 2017 , 89, 106-111	19.7	10
281	Perturbed CD8 T cell TIGIT/CD226/PVR axis despite early initiation of antiretroviral treatment in HIV infected individuals. <i>Scientific Reports</i> , 2017 , 7, 40354	4.9	42
280	Assessing cervical intraepithelial neoplasia as an indicator disease for HIV in a low endemic setting: a population-based register study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2017 , 124, 1680-1687	3.7	2
279	A high rate of HIV-1 acquisition post immigration among migrants in Sweden determined by a CD4 T-cell decline trajectory model. <i>HIV Medicine</i> , 2017 , 18, 677-684	2.7	18
278	The Human Immunodeficiency Virus Continuum of Care in European Union Countries in 2013: Data and Challenges. <i>Clinical Infectious Diseases</i> , 2017 , 64, 1644-1656	11.6	42
277	Evaluating the Impact of Functional Genetic Variation on HIV-1 Control. <i>Journal of Infectious Diseases</i> , 2017 , 216, 1063-1069	7	18
276	A21 HIV-1 sub-subtype F1 outbreak among MSM in Belgium. <i>Virus Evolution</i> , 2017 , 3,	3.7	3
275	Effect of therapy switch on time to second-line antiretroviral treatment failure in HIV-infected patients. <i>PLoS ONE</i> , 2017 , 12, e0180140	3.7	2
274	Prediction of coreceptor usage by five bioinformatics tools in a large Ethiopian HIV-1 subtype C cohort. <i>PLoS ONE</i> , 2017 , 12, e0182384	3.7	4
273	Quantitative humoral profiling of the HIV-1 proteome in elite controllers and patients with very long-term efficient antiretroviral therapy. <i>Scientific Reports</i> , 2017 , 7, 666	4.9	8

272	Richer gut microbiota with distinct metabolic profile in HIV infected Elite Controllers. <i>Scientific Reports</i> , 2017 , 7, 6269	4.9	56
271	Recent increased identification and transmission of HIV-1 unique recombinant forms in Sweden. <i>Scientific Reports</i> , 2017 , 7, 6371	4.9	10
270	Monophylogenetic HIV-1C epidemic in Ethiopia is dominated by CCR5-tropic viruses-an analysis of a prospective country-wide cohort. <i>BMC Infectious Diseases</i> , 2017 , 17, 37	4	10
269	Antiretroviral treatment for HIV infection: Swedish recommendations 2016. <i>Infectious Diseases</i> , 2017 , 49, 1-34	3.1	24
268	Sweden, the first country to achieve the Joint United Nations Programme on HIV/AIDS (UNAIDS)/World Health Organization (WHO) 90-90-90 continuum of HIV care targets. <i>HIV Medicine</i> , 2017 , 18, 305-307	2.7	81
267	CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 2869-2878	5.1	11
266	PhyloGeoTool: interactively exploring large phylogenies in an epidemiological context. <i>Bioinformatics</i> , 2017 , 33, 3993-3995	7.2	13
265	Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy. <i>PLoS ONE</i> , 2017 , 12, e0178942	3.7	11
264	Letter to the editor: Pre-exposure prophylaxis for HIV in Europe: The need for resistance surveillance. <i>Eurosurveillance</i> , 2017 , 22,	19.8	5
263	Six-week follow-up after HIV-1 exposure: a position statement from the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy. <i>Infectious Diseases</i> , 2016 , 48, 93-8	3.1	6
262	Multiplexed next-generation sequencing and de novo assembly to obtain near full-length HIV-1 genome from plasma virus. <i>Journal of Virological Methods</i> , 2016 , 236, 98-104	2.6	18
261	Impact of peer support on virologic failure in HIV-infected patients on antiretroviral therapy - a cluster randomized controlled trial in Vietnam. <i>BMC Infectious Diseases</i> , 2016 , 16, 759	4	8
260	The global spread of HIV-1 subtype B epidemic. <i>Infection, Genetics and Evolution</i> , 2016 , 46, 169-179	4.5	32
259	HIV-1 transmission between MSM and heterosexuals, and increasing proportions of circulating recombinant forms in the Nordic Countries. <i>Virus Evolution</i> , 2016 , 2, vew010	3.7	48
258	Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. <i>Lancet Infectious Diseases</i> , 2016 , 16, 565-575	25.5	175
257	Gut Microbiota Linked to Sexual Preference and HIV Infection. <i>EBioMedicine</i> , 2016 , 5, 135-46	8.8	230
256	Factors influencing the efficacy of rilpivirine in HIV-1 subtype C in low- and middle-income countries. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 367-71	5.1	6
255	Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe. <i>Clinical Infectious Diseases</i> , 2016 , 62, 655-663	11.6	117

254	Virological failure in patients with HIV-1 subtype C receiving antiretroviral therapy: an analysis of a prospective national cohort in Sweden. <i>Lancet HIV,the</i> , 2016 , 3, e166-74	7.8	35
253	Mutational Heterogeneity in p6 Gag Late Assembly (L) Domains in HIV-1 Subtype C Viruses from South Africa. <i>AIDS Research and Human Retroviruses</i> , 2016 , 32, 80-4	1.6	13
252	Symptomatic Patients without Epidemiological Indicators of HIV Have a High Risk of Missed Diagnosis: A Multi-Centre Cross Sectional Study. <i>PLoS ONE</i> , 2016 , 11, e0162503	3.7	7
251	Deficiencies in the health care system contribute to a high rate of late HIV diagnosis in Sweden. <i>HIV Medicine</i> , 2016 , 17, 425-35	2.7	30
250	Impact of immunosuppression and region of birth on risk of cervical intraepithelial neoplasia among migrants living with HIV in Sweden. <i>International Journal of Cancer</i> , 2016 , 139, 1471-9	7.5	9
249	Viral blips during suppressive antiretroviral treatment are associated with high baseline HIV-1 RNA levels. <i>BMC Infectious Diseases</i> , 2016 , 16, 305	4	23
248	Phylogenetic Analysis of Ethiopian HIV-1 Subtype C Near Full-Length Genomes Reveals High Intrasubtype Diversity and a Strong Geographical Cluster. <i>AIDS Research and Human Retroviruses</i> , 2016 , 32, 471-4	1.6	14
247	Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia. <i>Clinical Infectious Diseases</i> , 2016 , 63, 1245-1253	11.6	15
246	Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data. <i>HIV Medicine</i> , 2015 , 16, 297-306	2.7	8
245	Global Dispersal Pattern of HIV Type 1 Subtype CRF01_AE: A Genetic Trace of Human Mobility Related to Heterosexual Sexual Activities Centralized in Southeast Asia. <i>Journal of Infectious Diseases</i> , 2015 , 211, 1735-44	7	50
244	Role of translocated bacterial flagellin in monocyte activation among individuals with chronic HIV-1 infection. <i>Clinical Immunology</i> , 2015 , 161, 180-9	9	7
243	Reduced Levels of D-dimer and Changes in Gut Microbiota Composition After Probiotic Intervention in HIV-Infected Individuals on Stable ART. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015 , 70, 329-37	3.1	50
242	Gut microbiota diversity predicts immune status in HIV-1 infection. <i>Aids</i> , 2015 , 29, 2409-18	3.5	182
241	Multidimensional Clusters of CD4+ T Cell Dysfunction Are Primarily Associated with the CD4/CD8 Ratio in Chronic HIV Infection. <i>PLoS ONE</i> , 2015 , 10, e0137635	3.7	9
240	Arming of MAIT Cell Cytolytic Antimicrobial Activity Is Induced by IL-7 and Defective in HIV-1 Infection. <i>PLoS Pathogens</i> , 2015 , 11, e1005072	7.6	141
239	Efficacy and Safety of Antiretroviral Therapy Initiated One Week after Tuberculosis Therapy in Patients with CD4 Counts <i>PLoS ONE</i> , 2015 , 10, e0122587	3.7	20
238	Occasional spontaneous clearance of chronic hepatitis C virus in HIV-infected individuals. <i>Journal of Hepatology</i> , 2014 , 61, 957-61	13.4	29
237	Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe. <i>BMC Infectious Diseases</i> , 2014 , 14, 407	4	38

236	Cost-efficient HIV-1 drug resistance surveillance using multiplexed high-throughput amplicon sequencing: implications for use in low- and middle-income countries. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 3349-55	5.1	24
235	Temporal trends in the Swedish HIV-1 epidemic: increase in non-B subtypes and recombinant forms over three decades. <i>PLoS ONE</i> , 2014 , 9, e99390	3.7	40
234	Minority drug-resistant HIV-1 variants in treatment naïve East-African and Caucasian patients detected by allele-specific real-time PCR. <i>PLoS ONE</i> , 2014 , 9, e111042	3.7	9
233	Time on drug analysis based on real life data. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19790	5.4	
232	Drug resistance in non-B subtype HIV-1: impact of HIV-1 reverse transcriptase inhibitors. <i>Viruses</i> , 2014 , 6, 3535-62	6.2	22
231	T-bet and Eomes are differentially linked to the exhausted phenotype of CD8+ T cells in HIV infection. <i>PLoS Pathogens</i> , 2014 , 10, e1004251	7.6	182
230	Risk of HIV transmission from patients on antiretroviral therapy: a position statement from the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy. <i>Scandinavian Journal of Infectious Diseases</i> , 2014 , 46, 673-7		19
229	Prophylaxis and treatment of HIV-1 infection in pregnancy: Swedish recommendations 2013. <i>Scandinavian Journal of Infectious Diseases</i> , 2014 , 46, 401-11		5
228	High HCV treatment uptake in the Swedish HIV/HCV co-infected cohort. <i>Scandinavian Journal of Infectious Diseases</i> , 2014 , 46, 624-32		6
227	Novel tetra-peptide insertion in Gag-p6 ALIX-binding motif in HIV-1 subtype C associated with protease inhibitor failure in Indian patients. <i>Aids</i> , 2014 , 28, 2319-22	3.5	15
226	Minor viral population with drug-resistant mutation and risk of persistent low-level viremia or 'blips' in HIV-1 subtype C. <i>Aids</i> , 2014 , 28, 2635-6	3.5	2
225	Patterns of transmitted HIV drug resistance in Europe vary by risk group. <i>PLoS ONE</i> , 2014 , 9, e94495	3.7	28
224	Decreased phenotypic susceptibility to etravirine in patients with predicted genotypic sensitivity. <i>PLoS ONE</i> , 2014 , 9, e101508	3.7	3
223	Pattern of microbial translocation in patients living with HIV-1 from Vietnam, Ethiopia and Sweden. <i>Journal of the International AIDS Society</i> , 2014 , 17, 18841	5.4	9
222	Limited cross-border infections in patients newly diagnosed with HIV in Europe. <i>Retrovirology</i> , 2013 , 10, 36	3.6	39
221	HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics. <i>Retrovirology</i> , 2013 , 10, 7	3.6	103
220	HIV-1 fitness landscape models for indinavir treatment pressure using observed evolution in longitudinal sequence data are predictive for treatment failure. <i>Infection, Genetics and Evolution</i> , 2013 , 19, 349-60	4.5	3
219	Evolution of fibrosis during HCV recurrence after liver transplantation--influence of IL-28B SNP and response to peg-IFN and ribavirin treatment. <i>Journal of Viral Hepatitis</i> , 2013 , 20, 770-8	3.4	8

218	Evaluation of sequence ambiguities of the HIV-1 pol gene as a method to identify recent HIV-1 infection in transmitted drug resistance surveys. <i>Infection, Genetics and Evolution</i> , 2013 , 18, 125-31	4.5	43
217	Long-term efficacy and safety of atazanavir/ritonavir treatment in a real-life cohort of treatment-experienced patients with HIV type 1 infection. <i>AIDS Research and Human Retroviruses</i> , 2013 , 29, 564-73	1.6	8
216	497 SPONTANEOUS CLEARANCE OR CHRONIC EVOLUTION OF HCV IN HIV/HCV CO-INFECTED PATIENTS INFLUENCE OF THE IL28B GENOTYPE. <i>Journal of Hepatology</i> , 2013 , 58, S204	13.4	2
215	HCV RNA decline in chronic HCV genotype 2 and 3 during standard of care treatment according to IL28B polymorphism. <i>Journal of Viral Hepatitis</i> , 2013 , 20, 193-9	3.4	16
214	Lopinavir/ritonavir, atazanavir/ritonavir, and efavirenz in antiretroviral-naïve HIV-1-infected individuals over 144 weeks: an open-label randomized controlled trial. <i>Scandinavian Journal of Infectious Diseases</i> , 2013 , 45, 543-51		13
213	Oral antiretroviral drugs as public health tools for HIV prevention: global implications for adherence, drug resistance, and the success of HIV treatment programs. <i>Journal of Infectious Diseases</i> , 2013 , 207 Suppl 2, S101-6	7	20
212	AIDS and HIV Infection after Thirty Years. <i>AIDS Research and Treatment</i> , 2013 , 2013, 731983	2.3	1
211	Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe. <i>Journal of Infectious Diseases</i> , 2013 , 207, 1216-20	7	47
210	HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 1053-6	5.9	31
209	Evaluation of etravirine resistance in clinical samples by a simple phenotypic test. <i>Journal of Medical Virology</i> , 2013 , 85, 703-8	19.7	7
208	Activation, exhaustion, and persistent decline of the antimicrobial MR1-restricted MAIT-cell population in chronic HIV-1 infection. <i>Blood</i> , 2013 , 121, 1124-35	2.2	264
207	Superinfection with drug-resistant HIV is rare and does not contribute substantially to therapy failure in a large European cohort. <i>BMC Infectious Diseases</i> , 2013 , 13, 537	4	3
206	Human APOBEC3G-mediated hypermutation is associated with antiretroviral therapy failure in HIV-1 subtype C-infected individuals. <i>Journal of the International AIDS Society</i> , 2013 , 16, 18472	5.4	18
205	Kinetics of microbial translocation markers in patients on efavirenz or lopinavir/r based antiretroviral therapy. <i>PLoS ONE</i> , 2013 , 8, e55038	3.7	26
204	Long-term efficacy of first line antiretroviral therapy in Indian HIV-1 infected patients: a longitudinal cohort study. <i>PLoS ONE</i> , 2013 , 8, e55421	3.7	18
203	Clinical evaluation of Rega 8: an updated genotypic interpretation system that significantly predicts HIV-therapy response. <i>PLoS ONE</i> , 2013 , 8, e61436	3.7	16
202	Molecular dating of HIV-1 subtype C from Bangladesh. <i>PLoS ONE</i> , 2013 , 8, e79193	3.7	8
201	Feasibility and effectiveness of indicator condition-guided testing for HIV: results from HIDES I (HIV indicator diseases across Europe study). <i>PLoS ONE</i> , 2013 , 8, e52845	3.7	111

200	Trends in antiretroviral therapy and prevalence of HIV drug resistance mutations in Sweden 1997-2011. <i>PLoS ONE</i> , 2013 , 8, e59337	3.7	19
199	HIV care in the Swedish-Danish HIV cohort 1995-2010, closing the gaps. <i>PLoS ONE</i> , 2013 , 8, e72257	3.7	36
198	Transmitted drug resistance and phylogenetic analysis of HIV CRF01_AE in Northern Vietnam. <i>Infection, Genetics and Evolution</i> , 2012 , 12, 448-52	4.5	15
197	Optimizing background therapy in treatment-experienced HIV-1 patients by rules-based algorithms and bioinformatics. <i>Future Virology</i> , 2012 , 7, 749-757	2.4	2
196	Survival and causes of death among HIV-infected patients starting antiretroviral therapy in north-eastern Vietnam. <i>Scandinavian Journal of Infectious Diseases</i> , 2012 , 44, 201-8		31
195	Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naïve HIV-1 infected patients. <i>Retrovirology</i> , 2012 , 9, 81	3.6	21
194	Predicting response to antiretroviral treatment by machine learning: the EuResist project. <i>Intervirology</i> , 2012 , 55, 123-7	2.5	34
193	Use of InfCare HIV to identify and characterize suboptimally treated HIV patients at a Danish HIV clinic: a cross-sectional cohort study. <i>Scandinavian Journal of Infectious Diseases</i> , 2012 , 44, 108-14		8
192	Emergence of unique recombinant forms (URFs) in Indian HIV-1 epidemic: data from nationwide clinical cohort between 2007 and 2011. <i>Retrovirology</i> , 2012 , 9,	3.6	78
191	Monitoring the efficacy of antiretroviral therapy by a simple reverse transcriptase assay in HIV-infected adults in rural Vietnam. <i>Future Virology</i> , 2012 , 7, 923-931	2.4	8
190	Efficacy of antiretroviral therapy switch in HIV-infected patients: a 10-year analysis of the EuResist Cohort. <i>Intervirology</i> , 2012 , 55, 160-6	2.5	4
189	Higher prevalence of predicted X4-tropic strains in perinatally infected older children with HIV-1 subtype C in India. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012 , 59, 347-53	3.1	14
188	Low prevalence of transmitted drug resistance in patients newly diagnosed with HIV-1 infection in Sweden 2003-2010. <i>PLoS ONE</i> , 2012 , 7, e33484	3.7	51
187	Molecular epidemiology of HIV-1 subtypes in India: origin and evolutionary history of the predominant subtype C. <i>PLoS ONE</i> , 2012 , 7, e39819	3.7	56
186	Characterization of HIV-specific CD4+ T cell responses against peptides selected with broad population and pathogen coverage. <i>PLoS ONE</i> , 2012 , 7, e39874	3.7	19
185	European guidelines on the clinical management of HIV-1 tropism testing. <i>Lancet Infectious Diseases</i> , 2011 , 11, 394-407	25.5	194
184	High mobility group box protein-1 in HIV-1 infection. <i>Current HIV Research</i> , 2011 , 9, 6-10	1.3	18
183	Late presentation of HIV infection: a consensus definition. <i>HIV Medicine</i> , 2011 , 12, 61-4	2.7	279

182	Prediction of response to antiretroviral therapy by human experts and by the EuResist data-driven expert system (the EVE study). <i>HIV Medicine</i> , 2011 , 12, 211-8	2.7	24
181	Overcoming obstacles to late presentation for HIV infection in Europe. <i>HIV Medicine</i> , 2011 , 12, 246-9	2.7	6
180	Bilirubin-a potential marker of drug exposure in atazanavir-based antiretroviral therapy. <i>AAPS Journal</i> , 2011 , 13, 598-605	3.7	14
179	Rebound of residual plasma viremia after initial decrease following addition of intravenous immunoglobulin to effective antiretroviral treatment of HIV. <i>AIDS Research and Therapy</i> , 2011 , 8, 21	3	9
178	HIV-1 mutational pathways under multidrug therapy. <i>AIDS Research and Therapy</i> , 2011 , 8, 26	3	11
177	Prophylaxis and treatment of HIV-1 infection in pregnancy: Swedish recommendations 2010. <i>Scandinavian Journal of Infectious Diseases</i> , 2011 , 43, 411-23		9
176	Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 1886-96	5.1	39
175	Only slight impact of predicted replicative capacity for therapy response prediction. <i>PLoS ONE</i> , 2010 , 5, e9044	3.7	1
174	Antiretroviral therapy optimisation without genotype resistance testing: a perspective on treatment history based models. <i>PLoS ONE</i> , 2010 , 5, e13753	3.7	18
173	Implications of the release of high-mobility group box 1 protein from dying cells during human immunodeficiency virus type 1 infection in vitro. <i>Journal of General Virology</i> , 2010 , 91, 1800-9	4.9	26
172	Differential effects of efavirenz, lopinavir/r, and atazanavir/r on the initial viral decay rate in treatment naïve HIV-1-infected patients. <i>AIDS Research and Human Retroviruses</i> , 2010 , 26, 533-40	1.6	13
171	Elevated plasma levels of lipopolysaccharide and high mobility group box-1 protein are associated with high viral load in HIV-1 infection: reduction by 2-year antiretroviral therapy. <i>Aids</i> , 2010 , 24, 1733-7	3.5	54
170	The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patients. <i>European Journal of Clinical Pharmacology</i> , 2010 , 66, 349-57	2.8	22
169	A high occurrence of late presenters and missed HIV diagnosis in clinical care in Sweden. <i>Journal of the International AIDS Society</i> , 2010 , 13, P169	5.4	4
168	Long-term efficacy and safety of atazanavir/ritonavir treatment in a real-life cohort of treatment-experienced HIV patients. <i>Journal of the International AIDS Society</i> , 2010 , 13, P31-P31	5.4	1
167	Predicting the response to combination antiretroviral therapy: retrospective validation of geno2pheno-THEO on a large clinical database. <i>Journal of Infectious Diseases</i> , 2009 , 199, 999-1006	7	36
166	Transmission of drug-resistant HIV-1 is stabilizing in Europe. <i>Journal of Infectious Diseases</i> , 2009 , 200, 1503-8	7	186
165	Severe functional impairment and elevated PD-1 expression in CD1d-restricted NKT cells retained during chronic HIV-1 infection. <i>European Journal of Immunology</i> , 2009 , 39, 902-11	6.1	79

164	Selection of drug-resistant HIV-1 during the early phase of viral decay is uncommon in treatment-naïve patients initiated on a three- or four-drug antiretroviral regimen including lamivudine. <i>Journal of Medical Virology</i> , 2009 , 81, 1-8	19.7	3
163	Reduction of the HIV-1 reservoir in resting CD4+ T-lymphocytes by high dosage intravenous immunoglobulin treatment: a proof-of-concept study. <i>AIDS Research and Therapy</i> , 2009 , 6, 15	3	26
162	Kinetics of plasma cytokines and chemokines during primary HIV-1 infection and after analytical treatment interruption. <i>HIV Medicine</i> , 2009 , 10, 94-102	2.7	29
161	Difference in drug resistance patterns between minor HIV-1 populations in cerebrospinal fluid and plasma. <i>HIV Medicine</i> , 2009 , 10, 111-5	2.7	5
160	Treatment of HIV infection: Swedish recommendations 2009. <i>Scandinavian Journal of Infectious Diseases</i> , 2009 , 41, 788-807		15
159	Treatment of chronic hepatitis B infection: an update of Swedish recommendations. <i>Scandinavian Journal of Infectious Diseases</i> , 2008 , 40, 436-50		10
158	Selecting anti-HIV therapies based on a variety of genomic and clinical factors. <i>Bioinformatics</i> , 2008 , 24, i399-406	7.2	42
157	Prophylaxis and treatment of HIV-1 infection in pregnancy: Swedish Recommendations 2007. <i>Scandinavian Journal of Infectious Diseases</i> , 2008 , 40, 451-61		8
156	CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4beta-hydroxycholesterol levels. <i>European Journal of Clinical Pharmacology</i> , 2008 , 64, 775-81	2.8	50
155	Comparison of classifier fusion methods for predicting response to anti HIV-1 therapy. <i>PLoS ONE</i> , 2008 , 3, e3470	3.7	37
154	A structural equation modeling approach to the concepts of adherence and readiness in antiretroviral treatment. <i>Patient Education and Counseling</i> , 2007 , 67, 108-16	3.1	12
153	Presence of M184I/V in minor HIV-1 populations of patients with lamivudine and/or didanosine treatment failure. <i>HIV Medicine</i> , 2007 , 8, 504-10	2.7	5
152	Antiretroviral treatment of HIV infection: Swedish recommendations 2007. <i>Scandinavian Journal of Infectious Diseases</i> , 2007 , 39, 486-507		16
151	Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007 , 44, 417-22	3.1	69
150	Elevated plasma levels of high mobility group box protein 1 in patients with HIV-1 infection. <i>Aids</i> , 2007 , 21, 869-71	3.5	29
149	Authors' Response to Early Virologic Rebound in a Pilot Trial of Ritonavir-Boosted Atazanavir as Maintenance Monotherapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007 , 46, 118-119	3.1	
148	Early immune activation in gut-associated and peripheral lymphoid tissue during acute HIV infection. <i>Aids</i> , 2007 , 21, 565-74	3.5	58
147	Assessing and achieving readiness to initiate HIV medication. <i>Patient Education and Counseling</i> , 2006 , 62, 21-30	3.1	32

146	Antiretroviral treatment of HIV infection: Swedish recommendations 2005. <i>Scandinavian Journal of Infectious Diseases</i> , 2006 , 38, 86-103		5
145	Efficacy of nelfinavir-based treatment in the central nervous system of HIV-1 infected patients. <i>Scandinavian Journal of Infectious Diseases</i> , 2006 , 38, 371-4		9
144	HMGB1 activates replication of latent HIV-1 in a monocytic cell-line, but inhibits HIV-1 replication in primary macrophages. <i>Cytokine</i> , 2006 , 34, 17-23	4	34
143	Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. <i>Pharmacogenetics and Genomics</i> , 2006 , 16, 191-8	1.9	126
142	Adherence to treatment in Swedish HIV-infected patients. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2006 , 31, 605-16	2.2	38
141	Differences in adherence and motivation to HIV therapy--two independent assessments in 1998 and 2002. <i>International Journal of Clinical Pharmacy</i> , 2006 , 28, 248-56		15
140	Discrimination of lamivudine resistant minor HIV-1 variants by selective real-time PCR. <i>Journal of Virological Methods</i> , 2005 , 127, 100-7	2.6	11
139	Diverse pattern of protease inhibitor resistance mutations in HIV-1 infected patients failing nelfinavir. <i>Journal of Medical Virology</i> , 2005 , 76, 447-51	19.7	5
138	Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. <i>Journal of Infectious Diseases</i> , 2005 , 192, 607-17	7	98
137	Expansion of CD7(low) and CD7(negative) CD8 T-cell effector subsets in HIV-1 infection: correlation with antigenic load and reversion by antiretroviral treatment. <i>Blood</i> , 2004 , 104, 3672-8	2.2	28
136	Updated European Recommendations for the Clinical Use of HIV Drug Resistance Testing. <i>Antiviral Therapy</i> , 2004 , 9, 829-848	1.6	73
135	Intracellular high mobility group B1 protein (HMGB1) represses HIV-1 LTR-directed transcription in a promoter- and cell-specific manner. <i>Virology</i> , 2003 , 314, 179-89	3.6	39
134	Inter-laboratory comparison of HCV-RNA assay results: implications for multi-centre research. <i>Journal of Medical Virology</i> , 2003 , 69, 195-201	19.7	11
133	Painful and non-painful neuropathy in HIV-infected patients: an analysis of somatosensory nerve function. <i>European Journal of Pain</i> , 2003 , 7, 23-31	3.7	47
132	Follow-up of antiretroviral treatment in liver transplant recipients with primary and chronic HIV type 1 infection. <i>AIDS Research and Human Retroviruses</i> , 2003 , 19, 13-9	1.6	13
131	Antiretroviral treatment of human immunodeficiency virus infection: Swedish recommendations. <i>Scandinavian Journal of Infectious Diseases</i> , 2003 , 35, 155-67		13
130	Use of genotypic assays for the detection of antiretroviral resistance: a legal proceeding, Rome, 22-23 April 2002. <i>Scandinavian Journal of Infectious Diseases</i> , 2003 , 106, 5		
129	Persistence of earlier HIV-1 drug resistance mutations at new treatment failure. <i>Journal of Medical Virology</i> , 2002 , 68, 473-8	19.7	12

128	Plasma levels of soluble CD27: a simple marker to monitor immune activation during potent antiretroviral therapy in HIV-1-infected subjects. <i>Clinical and Experimental Immunology</i> , 2002 , 127, 486-94	6.2	37
127	Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy. <i>Aids</i> , 2002 , 16, 1039-44	3.5	86
126	Accumulation of DC-SIGN+CD40+ dendritic cells with reduced CD80 and CD86 expression in lymphoid tissue during acute HIV-1 infection. <i>Aids</i> , 2002 , 16, 683-92	3.5	115
125	Low levels of perforin expression in CD8+ T lymphocyte granules in lymphoid tissue during acute human immunodeficiency virus type 1 infection. <i>Journal of Infectious Diseases</i> , 2002 , 185, 1355-8	7	53
124	Quantification of human immunodeficiency virus type 1 proviral DNA by the TaqMan real-time PCR assay. <i>Journal of Clinical Microbiology</i> , 2002 , 40, 3883-4	9.7	30
123	Monophyletic HIV type 1 CRF02-AG in a nosocomial outbreak in Benghazi, Libya. <i>AIDS Research and Human Retroviruses</i> , 2002 , 18, 727-32	1.6	27
122	Broad spectrum of time of detection, primary symptoms and disease progression in infants with HIV-1 infection. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2001 , 20, 159-66	5.3	3
121	Quantitative single cell methods that identify cytokine and chemokine expression in dendritic cells. <i>Journal of Immunological Methods</i> , 2001 , 249, 207-22	2.5	11
120	Recent origin of human immunodeficiency virus type 1 variants in resting CD4+ T lymphocytes in untreated and suboptimally treated subjects. <i>Journal of Infectious Diseases</i> , 2001 , 184, 1392-401	7	13
119	Kinetics of HIV-1 RNA and resistance-associated mutations after cessation of antiretroviral combination therapy. <i>Aids</i> , 2001 , 15, 1359-68	3.5	23
118	Smaller amounts of antiretroviral drugs are needed when combined with an active ribozyme against HIV-1. <i>Molecular Therapy</i> , 2001 , 3, 531-5	11.7	5
117	Initiation of therapy during primary HIV type 1 infection results in a continuous decay of proviral DNA and a highly restricted viral evolution. <i>AIDS Research and Human Retroviruses</i> , 2001 , 17, 409-16	1.6	23
116	Switching antiretroviral therapy from an enzyme-inducing drug. <i>Therapeutic Drug Monitoring</i> , 2000 , 22, 637-8	3.2	
115	Diagnosis of primary HIV-1 infection and duration of follow-up after HIV exposure. Karolinska Institute Primary HIV Infection Study Group. <i>Aids</i> , 2000 , 14, 2333-9	3.5	92
114	Rapid and simple determination of indinavir in serum, urine, and cerebrospinal fluid using high-performance liquid chromatography. <i>Therapeutic Drug Monitoring</i> , 2000 , 22, 626-9	3.2	11
113	The QUEST trial, a paradigm of HIV collaborative research. <i>Nature Medicine</i> , 2000 , 6, 1194	50.5	8
112	Antiretroviral therapy may improve sensory function in HIV-infected patients: a pilot study. <i>Neurology</i> , 2000 , 54, 2120-7	6.5	50
111	Viral dynamics in primary HIV-1 infection. Karolinska Institutet Primary HIV Infection Study Group. <i>Aids</i> , 2000 , 14, 2283-91	3.5	80

110	Variability and immunogenicity of human immunodeficiency virus type 1 p24 gene quasispecies. <i>Vaccine Journal</i> , 2000 , 7, 377-83		6
109	High plasma levels of soluble fas in HIV type 1-infected subjects are not normalized during highly active antiretroviral therapy. <i>AIDS Research and Human Retroviruses</i> , 2000 , 16, 1379-84	1.6	13
108	HIV-1 exposed dendritic cells show increased pro-inflammatory cytokine production but reduced IL-1ra following lipopolysaccharide stimulation. <i>Aids</i> , 1999 , 13, 2013-21	3.5	23
107	HIV viral load and response to antileishmanial chemotherapy in co-infected patients. <i>Aids</i> , 1999 , 13, 1921-5	3.5	57
106	Longitudinal quantification of human immunodeficiency virus type 1 DNA and RNA in long-term nonprogressors. <i>Journal of Infectious Diseases</i> , 1999 , 179, 1542-8	7	22
105	Relation between GB virus C/hepatitis G virus and fulminant hepatic failure may be secondary to treatment with contaminated blood and/or blood products. <i>Gut</i> , 1999 , 44, 274-8	19.2	9
104	Long-term pattern of HIV-1 RNA load in perinatally infected children. <i>Scandinavian Journal of Infectious Diseases</i> , 1999 , 31, 337-43		11
103	No association of HIV type 1 long terminal repeat sequence pattern with long-term nonprogression and in vivo viral replication levels in European subjects. <i>AIDS Research and Human Retroviruses</i> , 1999 , 15, 609-17	1.6	8
102	Phenotypic characteristics of human immunodeficiency virus type 1 subtype C isolates of Ethiopian AIDS patients. <i>AIDS Research and Human Retroviruses</i> , 1999 , 15, 647-53	1.6	127
101	Similar HIV-1 subtype A V3 loop sequences are found in dual HIV-1/HIV-2 and HIV-1-only seropositives in Ghana. <i>AIDS Research and Human Retroviruses</i> , 1999 , 15, 775-9	1.6	2
100	DNA sequence of the long terminal repeat of human immunodeficiency virus type 1 subtype A through G. <i>AIDS Research and Human Retroviruses</i> , 1999 , 15, 485-8	1.6	24
99	Long-term effects of antiretroviral combination therapy on HIV type 1 DNA levels. <i>AIDS Research and Human Retroviruses</i> , 1999 , 15, 1249-54	1.6	17
98	Pain in ambulatory HIV-infected patients with and without intravenous drug use. <i>European Journal of Pain</i> , 1999 , 3, 157-164	3.7	28
97	Long terminal repeat promoter/enhancer activity of different subtypes of HIV type 1. <i>AIDS Research and Human Retroviruses</i> , 1999 , 15, 1293-303	1.6	78
96	Limited humoral immunity in hepatitis C virus infection. <i>Gastroenterology</i> , 1999 , 116, 135-43	13.3	135
95	Perforin is not co-expressed with granzyme A within cytotoxic granules in CD8 T lymphocytes present in lymphoid tissue during chronic HIV infection. <i>Aids</i> , 1999 , 13, 1295-303	3.5	89
94	The anti-HBs response after 2 different accelerated intradermal and intramuscular schemes for hepatitis B vaccination. <i>Scandinavian Journal of Infectious Diseases</i> , 1999 , 31, 93-5		10
93	Indinavir-based treatment of HIV-1 infected patients: efficacy in the central nervous system. <i>Aids</i> , 1999 , 13, 1227-32	3.5	58

92	Kinetics of Chemokine Levels during Anti-HIV Therapy. <i>Antiviral Therapy</i> , 1999 , 4, 109-115	1.6	5
91	Detection of hepatitis G virus/GB virus C after allogeneic bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 1998 , 22, 499-501	4.4	5
90	Immunocytochemical detection of cytokines and chemokines in Langerhans cells and in vitro derived dendritic cells. <i>Journal of Immunological Methods</i> , 1998 , 214, 97-111	2.5	42
89	Human and murine antibody recognition is focused on the ATPase/helicase, but not the protease domain of the hepatitis C virus nonstructural 3 protein. <i>Hepatology</i> , 1998 , 28, 219-24	11.2	17
88	Variation in the hepatitis C virus NS5a region in relation to hypervariable region 1 heterogeneity during interferon treatment. <i>Journal of Medical Virology</i> , 1998 , 56, 33-8	19.7	28
87	Distribution of the CCR5 gene 32 base pair deletion and SDF1-3'A variant in healthy individuals from different populations. <i>Immunogenetics</i> , 1998 , 48, 417-9	3.2	40
86	Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. <i>Lancet, The</i> , 1998 , 351, 83-7	40	546
85	Nonsynonymous mutations within the human immunodeficiency virus type 1 p17 gene are clustered to sequences binding to the host human leukocyte antigen class I molecules. <i>AIDS Research and Human Retroviruses</i> , 1998 , 14, 241-8	1.6	23
84	Full-length sequence of human immunodeficiency virus type 1 subtype A, recombined with subtype C in the env V3 domain. <i>AIDS Research and Human Retroviruses</i> , 1998 , 14, 289-92	1.6	9
83	Coexisting members of HIV-1 p17 gene quasispecies represent proteins with distinct antigenicity and immunogenicity. <i>Aids</i> , 1998 , 12, 1973-81	3.5	6
82	Comparison of 3 quantitative HCV RNA assays--accuracy of baseline viral load to predict treatment outcome in chronic hepatitis C. <i>Scandinavian Journal of Infectious Diseases</i> , 1998 , 30, 441-6		36
81	Pronounced anti-HIV-1 activity of foscarnet in patients without cytomegalovirus infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1998 , 18, 51-3		12
80	Cerebrospinal fluid mononuclear cell counts influence CSF HIV-1 RNA levels. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1998 , 17, 214-9		41
79	Variations in HIV-1 pol gene associated with reduced sensitivity to antiretroviral drugs in treatment-naive patients. <i>Aids</i> , 1998 , 12, 2369-75	3.5	49
78	Characterization of the viral population during primary HIV-1 infection. <i>Aids</i> , 1998 , 12, 839-47	3.5	43
77	Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries. <i>Aids</i> , 1998 , 12, 2007-15	3.5	69
76	Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. Abacavir Phase 2 Clinical Team. <i>Aids</i> , 1998 , 12, F203-9	3.5	71
75	Combination Treatment for Hepatitis C Can be Hazardous in Patients Co-Infected with HIV. <i>Antiviral Therapy</i> , 1998 , 3, 233-234	1.6	1

74	Dynamics of the HIV-1 subtype distribution in the Swedish HIV-1 epidemic during the period 1980 to 1993. <i>AIDS Research and Human Retroviruses</i> , 1997 , 13, 343-5	1.6	34
73	Genetic evidence for mother-to-infant transmission of hepatitis G virus. <i>Journal of Infectious Diseases</i> , 1997 , 176, 281-5	7	59
72	Variation of hepatitis C virus hypervariable region 1 in immunocompromised patients. <i>Journal of Infectious Diseases</i> , 1997 , 175, 938-43	7	33
71	Subtype-specific problems with quantification of plasma HIV-1 RNA. <i>Aids</i> , 1997 , 11, 859-65	3.5	118
70	Genotyping of hepatitis C virus performed by type-specific PCR in comparison to nucleotide sequencing of NS5 and core regions. <i>Research in Virology</i> , 1997 , 148, 233-7		3
69	Indinavir in cerebrospinal fluid of HIV-1-infected patients. <i>Lancet, The</i> , 1997 , 350, 1823	40	31
68	Cerebrospinal fluid analyses in HIV patients: a longitudinal study through six years. <i>European Journal of Neurology</i> , 1997 , 4, 576-585	6	1
67	Quantification of HIV-1 proviral DNA from peripheral blood mononuclear cells using a high throughput four-competitor competitive PCR. <i>Journal of Virological Methods</i> , 1997 , 69, 171-80	2.6	17
66	Nosocomial transmission of hepatitis C virus. <i>Infection</i> , 1997 , 25, 74-7	5.8	42
65	Antibody production against hepatitis C virus core and nonstructural 3 proteins is highly sensitive to deficits in T-cell function. <i>Vaccine Journal</i> , 1997 , 4, 104-6		5
64	HIV-1 subtype C epidemic in Ethiopia. <i>Aids</i> , 1997 , 11, 1897	3.5	4
63	Dynamic analysis of hepatitis C virus polymorphism in patients with orthotopic liver transplantation. <i>Transplantation</i> , 1997 , 64, 170-2	1.8	16
62	Prevalence and risk factors for HTLV-II infection in 913 injecting drug users in Stockholm, 1994. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1997 , 15, 381-6		20
61	A novel ribozyme target site located in the HIV-1 nef open reading frame. <i>Virology</i> , 1996 , 219, 161-9	3.6	25
60	Effect of N-acetylcysteine(NAC) treatment on HIV-1 infection: a double-blind placebo-controlled trial. <i>European Journal of Clinical Pharmacology</i> , 1996 , 50, 457-61	2.8	83
59	Discrepancy of hepatitis C virus genotypes as determined by phylogenetic analysis of partial NS5 and core sequences. <i>Journal of Medical Virology</i> , 1996 , 49, 155-60	19.7	43
58	Site-directed serology of HIV-1 subtype B infection: relation between virus specific antibody levels and disease progression. <i>Clinical and Experimental Immunology</i> , 1996 , 106, 35-9	6.2	4
57	Restriction of hepatitis C virus heterogeneity during prolonged interferon-alpha therapy in relation to changes in virus load. <i>Journal of Infectious Diseases</i> , 1996 , 173, 992-6	7	15

56	Full-length sequence of an ethiopian human immunodeficiency virus type 1 (HIV-1) isolate of genetic subtype C. <i>AIDS Research and Human Retroviruses</i> , 1996 , 12, 1329-39	1.6	73
55	Transmission of hepatitis C virus by transfusion in Orebro County, Sweden, 1990-1992. <i>Scandinavian Journal of Infectious Diseases</i> , 1995 , 27, 449-52		20
54	Multiple enhancer motifs in HIV type 1 strains from Ethiopia. <i>AIDS Research and Human Retroviruses</i> , 1995 , 11, 761-4	1.6	28
53	Distinguishing acute from symptomatic chronic hepatitis C virus (HCV) infection by site-directed serology of the HCV structural proteins. <i>Journal of Infectious Diseases</i> , 1995 , 171, 1356-9	7	13
52	Human immunodeficiency virus type 1-infected patients with no disease progression display high-avidity antibody production to autologous V3 sequences. <i>Journal of Infectious Diseases</i> , 1995 , 171, 509-11	7	16
51	Efficacy of Human Leucocyte Alpha-Interferon Treatment for Chronic Hepatitis C Virus Infection. <i>Scandinavian Journal of Infectious Diseases</i> , 1995 , 27, 319-324		12
50	Prevention of nosocomial transmission of hepatitis C virus. <i>Lancet, The</i> , 1995 , 346, 190	40	7
49	Evaluation of a multiple peptide assay for typing of antibodies to the hepatitis C virus: relation to genomic typing by the polymerase chain reaction. <i>Journal of Medical Virology</i> , 1995 , 45, 50-5	19.7	15
48	Detection of hepatitis C virus RNA in the cell fraction of saliva before and after oral surgery. <i>Journal of Medical Virology</i> , 1995 , 45, 223-6	19.7	40
47	Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone. <i>Journal of Medical Virology</i> , 1995 , 46, 43-7	19.7	85
46	Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment. <i>Hepatology</i> , 1995 , 21, 918-922	11.2	77
45	Levels of hepatitis C virus (HCV) RNA in serum and their relationship to levels of immunoglobulin M and G antibodies against HCV core protein. <i>Journal of Clinical Microbiology</i> , 1995 , 33, 778-80	9.7	13
44	Dynamic analysis of heterogeneous hepatitis C virus populations by direct solid-phase sequencing. <i>Journal of Clinical Microbiology</i> , 1995 , 33, 1870-4	9.7	20
43	Variability of the E2/NS1 region of Swedish hepatitis C virus strains and its correlation to genotypes. <i>Scandinavian Journal of Infectious Diseases</i> , 1994 , 26, 255-61		1
42	Evidence of no change in V3 loop antibody recognition pattern in HIV type 1-infected Ethiopians between 1988 and 1993. <i>AIDS Research and Human Retroviruses</i> , 1994 , 10, 1551-6	1.6	18
41	Hepatitis C virus replication in liver and peripheral blood mononuclear cells of interferon-alpha-treated and untreated patients with chronic hepatitis C. <i>Scandinavian Journal of Gastroenterology</i> , 1994 , 29, 82-6	2.4	19
40	Parvovirus B19 infection in HIV-1 infected patients with anemia. <i>Infection</i> , 1994 , 22, 356-8	5.8	23
39	Colorimetric detection of competitive PCR products for quantification of hepatitis C viremia. <i>Journal of Virological Methods</i> , 1994 , 47, 1-13	2.6	29

38	A cell-binding Arg-Gly-Asp sequence is present in close proximity to the major linear antigenic region of HCV NS3. <i>Biochemical and Biophysical Research Communications</i> , 1994 , 202, 1352-6	3.4	9
37	Rapid grouping of HIV-1 infection in subtypes A to E by V3 peptide serotyping and its relation to sequence analysis. <i>Biochemical and Biophysical Research Communications</i> , 1994 , 205, 1658-64	3.4	34
36	Serum hepatitis C virus RNA levels in chronic hepatitis C--importance for outcome of interferon alfa-2b treatment. <i>Scandinavian Journal of Infectious Diseases</i> , 1994 , 26, 263-70		29
35	Antigenic structure of the complete nonstructural (NS) 2 and 5 proteins of hepatitis C virus (HCV): anti-HCV NS2 and NS5 antibody reactivities in relation to HCV serotype, presence of HCV RNA, and acute HCV infection. <i>Vaccine Journal</i> , 1994 , 1, 290-4		15
34	Sequence analysis of selected regions of the env (V3 loop and gp41) and gag (p7) reading frames of Ethiopian human immunodeficiency virus type 1 strains. <i>Archives of Virology</i> , 1993 , 128, 229-39	2.6	20
33	Neutralizing antibody response during human immunodeficiency virus type 1 infection: type and group specificity and viral escape. <i>Journal of General Virology</i> , 1993 , 74 (Pt 5), 855-63	4.9	63
32	Transmission of zidovudine-resistant HIV-1. <i>Aids</i> , 1993 , 7, 1684-5	3.5	17
31	Detection of hepatitis C virus (HCV) RNA by PCR related to HCV antibodies in serum and liver histology in Swedish blood donors. <i>Journal of Medical Virology</i> , 1993 , 39, 57-61	19.7	55
30	Immunoglobulin M reactivity towards the immunologically active region sp75 of the core protein of hepatitis C virus (HCV) in chronic HCV infection. <i>Journal of Medical Virology</i> , 1993 , 39, 325-32	19.7	33
29	Hepatitis C viral RNA titers in serum prior to, during, and after oral treatment with ribavirin for chronic hepatitis C. <i>Journal of Medical Virology</i> , 1993 , 41, 99-102	19.7	78
28	The neurotoxin-like sequence of human immunodeficiency virus gp120: a comparison of sequence data from patients with and without neurological symptoms. <i>Virus Genes</i> , 1993 , 7, 23-31	2.3	7
27	Relationship between cell-free viraemia, antigenaemia and antibody levels in HIV-1-infected Ethiopian patients. <i>Aids</i> , 1992 , 6, 651-7	3.5	14
26	Response of Ethiopian human immunodeficiency virus type 1 isolates to antiviral compounds. <i>Antiviral Research</i> , 1992 , 19, 353-9	10.8	1
25	Intrauterine and intrapartum transmission of HIV. <i>Lancet, The</i> , 1992 , 339, 245-6	4.0	17
24	Combined treatment of symptomatic human immunodeficiency virus type 1 infection with native interferon-alpha and zidovudine. <i>Journal of Infectious Diseases</i> , 1991 , 163, 710-5	7	34
23	Detection of HIV-1 DNA and infectious virus in cerebrospinal fluid. <i>AIDS Research and Human Retroviruses</i> , 1991 , 7, 369-73	1.6	24
22	Interferon-alpha and tumor necrosis factor-alpha in serum of patients in various stages of HIV-1 infection. <i>AIDS Research and Human Retroviruses</i> , 1991 , 7, 375-80	1.6	180
21	HIV in pregnant women and their offspring: evidence for late transmission. <i>Lancet, The</i> , 1991 , 338, 203-740		187

20	Hepatitis C virus infection in individuals with or without human immunodeficiency virus type 1 infection. <i>Infection</i> , 1990 , 18, 347-51	5.8	19
19	Detection of human immunodeficiency virus-1 by polymerase chain reaction and virus cultivation. <i>Journal of Medical Virology</i> , 1990 , 31, 234-40	19.7	25
18	Quantitative detection of brain aberrations in human immunodeficiency virus type 1-infected individuals by magnetic resonance imaging. <i>Journal of Infectious Diseases</i> , 1990 , 162, 1245-51	7	31
17	Treatment of HIV-1 Infected Patients with Peptide T. <i>Antiviral Chemistry and Chemotherapy</i> , 1990 , 1, 349-354	3.5	
16	New subtype of HIV-1 in Ethiopia. <i>Lancet, The</i> , 1990 , 336, 942	40	15
15	Fine analysis of intrathecally synthesized anti-HIV IgG1-4 by peptide mapping. <i>Journal of the Neurological Sciences</i> , 1990 , 100, 31-6	3.2	4
14	Detection of cell-free human immunodeficiency virus in cerebrospinal fluid by using immune scanning electron microscopy. <i>Journal of Infectious Diseases</i> , 1989 , 159, 1037-41	7	13
13	Non-specific reactivity in HIV antigen assay of sera from organ transplant recipients. <i>Infection</i> , 1989 , 17, 168-9	5.8	
12	Relationship between the occurrence of virus in plasma and cerebrospinal fluid of HIV-1 infected individuals. <i>Journal of Medical Virology</i> , 1989 , 27, 258-63	19.7	10
11	IgG subclass reactivity against human immunodeficiency virus (HIV) and cytomegalovirus in cerebrospinal fluid and serum from HIV-infected patients. <i>Journal of Medical Virology</i> , 1988 , 25, 17-26	19.7	23
10	Efficient isolation of HIV from plasma during different stages of HIV infection. <i>Journal of Medical Virology</i> , 1988 , 26, 23-32	19.7	83
9	IgG subclasses of antibodies reacting with HIV and myelin basic protein in CSF from HIV infected patients. <i>Journal of Neuroimmunology</i> , 1988 , 17, 258-259	3.5	78
8	Declining levels of HIV P24 antigen in serum during treatment with foscarnet. <i>Lancet, The</i> , 1988 , 1, 1052	40	22
7	Isolation frequency of human immunodeficiency virus from cerebrospinal fluid and blood of patients with varying severity of HIV infection. <i>AIDS Research and Human Retroviruses</i> , 1988 , 4, 351-8	1.6	60
6	Increased production of malondialdehyde in patients with HIV infection. <i>Scandinavian Journal of Infectious Diseases</i> , 1988 , 20, 287-90		107
5	Detection of immunoglobulin M antibody in primary human immunodeficiency virus infection. <i>Aids</i> , 1988 , 2, 11-5	3.5	37
4	Antigen detection in primary HIV infection. <i>British Medical Journal</i> , 1988 , 296, 238-40		90
3	Isolation of human immunodeficiency virus (HIV) from plasma during primary HIV infection. <i>Journal of Medical Virology</i> , 1987 , 23, 67-73	19.7	95

- | | | | |
|---|--|-----|-----|
| 2 | Characteristics of the specific cell-mediated immune response in human immunodeficiency virus infection. <i>Journal of Virology</i> , 1987 , 61, 2017-23 | 6.6 | 139 |
| 1 | Nitroblue tetrazolium (NBT) reduction by neutrophilic granulocytes in patients with HTLV-III infection. <i>Scandinavian Journal of Infectious Diseases</i> , 1986 , 18, 101-3 | | 22 |